ArticleScientific reports2024
Circulating levels of neurofilament light chain as a biomarker of infarct and white matter hyperintensity volumes after ischemic stroke.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Pooled it
- Diagnostic and prognostic value of blood neurofilament light chain in ischemic stroke: an individual patient data meta-analysis.Journal of neurology · 2026Pooled it
- Neurofilament light chain dynamics following ischemic stroke and their modulation by transauricular vagus nerve stimulation.Scientific reports · 2026Trial
- Next-Generation Stroke Biomarkers: Bridging the Gap Between Innovation and Translation.Journal of clinical medicine · 2026Review
- Renal Function and Serum Neurofilament Light Chain in Acute Ischemic Stroke: An Observational Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- From Bench to Bedside: Neurofilament Light Chain as a Biomarker in Ischemic Stroke.Current medical science · 2026Review
- Lower baseline serum neuronal-specific enolase levels predict better rate of recovery of functional walking ability in post-acute stroke patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Toward Precision Post-Stroke Rehabilitation Medicine: Integrating Molecular, Imaging, and Computational Biomarkers for Functional Outcome Prediction.Journal of clinical medicine · 2025Review
- Serum Biomarkers in Acute Ischemic Stroke: Clinical Applications and Emerging Insights.Journal of clinical medicine · 2025Review
- Plasma brain-derived tau correlates with cerebral infarct volume.Journal of internal medicine · 2025Article
- Local arrangement of microfibrillar-associated protein 5 with neurovascular and extracellular components in non- and ischemia-affected brain regions of mice.Frontiers in neuroscience · 2025Article
- Neuroinflammation and acute ischemic stroke: impact on translational research and clinical care.Frontiers in surgery · 2025Review
- Neurological Biomarker Profiles in Royal Canadian Air Force (RCAF) Pilots and Aircrew.Brain sciences · 2024Article
- Diagnostic biomarkers of ischemic stroke: strengths and limitations across blood, urine, and saliva.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Serum neurofilament light chain protein (sNfL) shows promise as a biomarker for infarct size in acute ischemic stroke and for monitoring cerebral small vessel disease (cSVD). However, distinguishing the cSVD contribution after stroke may not be possible due to post-stroke sNfL increase. Additionally, it remains unclear if etiologic subtype differences exist. We measured infarct and white matter hyperintensity (WMH) volumes using MRI at the index stroke in ischemic stroke patients (n = 316, mean age 53 years, 65% males) and at 7-year follow-up (n = 187). Serum NfL concentration was measured in the acute phase (n = 235), at 3-months (n = 288), and 7-years (n = 190) post stroke. In multivariable regression, acute and 3-month sNfL concentrations were associated with infarct volume and time since stroke, but not with stroke etiology or infarct location. Seven years post-stroke, sNfL was associated with WMHs and age, but not with stroke etiology. Nonlinear regression estimated that sNfL peaks around 1 month, and declines by 50% at 3 months, and 99% at 9 months. We conclude that sNfL can indicate infarct volume and time since brain injury in the acute and subacute phases after stroke. Due to the significant post-stroke sNfL increase, several months are needed for reliable assessment of cSVD activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.